Notable 52-Week Highs and Lows 9/6: (NAV) (CLCD) (XIN) High; (TNXP) (ETRM) Low

September 6, 2016 3:26 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

52-Week High:
  • Navistar International Corporation (NYSE: NAV) $23.45. Navistar International announced that it has formed a wide-ranging strategic alliance with Volkswagen Truck & Bus, which includes an equity investment in Navistar by Volkswagen Truck & Bus and framework agreements for strategic technology and supply collaboration and a procurement joint venture.

  • CoLucid Pharmaceuticals, Inc. (Nasdaq: CLCD) $24.65. CoLucid Pharmaceuticals announced that its Phase 3 pivotal study evaluating lasmiditan, the SAMURAI study, achieved both the primary and key secondary efficacy endpoints with statistical significance (p < 0.001). Lasmiditan was also well tolerated. SAMURAI was a randomized, double-blind, placebo-controlled parallel group study designed to evaluate the efficacy and safety of lasmiditan (100 mg and 200 mg) in comparison to placebo.

  • Xinyuan Real Estate Co., Ltd. (NYSE: XIN) $6.85. Xinyuan Real Estate Co. announced that the Company has appointed Mr. Wells Tian, previously an independent director, as an executive director. Mr. Tian will no longer serve as a member of the Board's Audit Committee.
52-Week Low:
  • Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) $0.92. Tonix Pharma announced preliminary topline results from its Phase 3 clinical study, AFFIRM, designed to evaluate the safety and efficacy of TNX-102 SL (cyclobenzaprine HCl sublingual tablets), 2.8 mg, in patients with fibromyalgia. The AFFIRM data did not achieve statistical significance in the primary efficacy endpoint: the proportion of patients who reported a 30 percent or greater reduction in pain from baseline to the end of the 12-week treatment period based on the pre-specified primary analysis

  • EnteroMedics Inc. (Nasdaq: ETRM) $0.12. EnteroMedics filed a preliminary proxy statement late last Friday. For more color, click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Special Reports

Add Your Comment